Zynlonta Disease Interactions
There are 2 disease interactions with Zynlonta (loncastuximab tesirine).
Loncastuximab tesirine (applies to Zynlonta) hepatic impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
Patients with mild hepatic impairment should be monitored for a potential increase of adverse effects when using loncastuximab tesirine. This drug has not been studied in patients with moderate or severe hepatic impairment.
References (1)
- (2021) "Product Information. Zynlonta (loncastuximab tesirine)." ADC Therapeutics America
Loncastuximab tesirine (applies to Zynlonta) kidney disease
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction
The effects of severe renal impairment and end-stage renal disease in the pharmacokinetics of loncastuximab tesirine is unknown.
References (1)
- (2021) "Product Information. Zynlonta (loncastuximab tesirine)." ADC Therapeutics America
Switch to consumer interaction data
Zynlonta drug interactions
There are 523 drug interactions with Zynlonta (loncastuximab tesirine).
Report options
More about Zynlonta (loncastuximab tesirine)
- Zynlonta consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous antineoplastics
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Rituxan
Rituxan infusion is used to treat certain leukemias and lymphomas and some non-cancer conditions ...
Truxima
Truxima is used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid ...
Monjuvi
Monjuvi (tafasitamab-cxix) is used for the treatment of relapsed or refractory diffuse large B-cell ...
Kymriah
Kymriah is used to treat acute lymphoblastic leukemia (ALL) that is relapsing or refractory in ...
Yescarta
Yescarta is used to treat large B-cell lymphoma and follicular lymphoma, two types of non-Hodgkin ...
Breyanzi
Breyanzi is a CAR T cell therapy for large B-cell lymphoma, CLL/SLL, follicular lymphoma, mantle ...
Polivy
Polivy (polatuzumab vedotin-piiq) is a targeted treatment that may be used to treat diffuse large ...
Xpovio
Xpovio is used to treat multiple myeloma (MM) or relapsed/refractory diffuse large B-cell lymphoma ...
Lunsumio
Lunsumio (mosunetuzumab-axgb) is used for the treatment of relapsed or refractory follicular ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
